Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that on Monday, Jan. 26, 2026, at 8:30 am Eastern Time, the Company will host a ...
Researchers at Kumamoto University have demonstrated that iron supplementation can significantly alleviate muscle pathology and functional decline in a mouse model of facioscapulohumeral muscular ...
“MAID gave me the freedom to determine my own fate,” said Jeremy Boal ...
An international team of scientists has designed a new type of therapy to target the mutant toxic RNA that causes myotonic ...
Morning Overview on MSN
He went to prison for gene-edited babies, now he plans a shocking sequel
He Jiankui’s name became synonymous with scientific transgression when his secret experiment produced the world’s first gene-edited babies. After serving a prison sentence in China, he is back in the ...
Researchers at Kumamoto University have demonstrated that iron supplementation can significantly alleviate muscle pathology and functional decline in a mouse model of facioscapulohumeral muscular ...
FDA has requested the HOPE-3 clinical study report (CSR) as part of the BLA review processCompany expects to submit updates to the BLA in ...
Zeleciment basivarsen (z-basivarsen) demonstrated sustained functional improvement across multiple clinical measures in the ongoing ACHIEVE ...
Researchers from Carnegie Mellon University have discovered a way to target RNA that could lead to new treatment options for ...
Endoxifen program into rare pediatric neuromuscular disease along with previously received Rare Pediatric Disease Designation SEATTLE, /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback